Edmond DE Rothschild Holding S.A. Acquires 3,236 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Edmond DE Rothschild Holding S.A. increased its stake in Thermo Fisher Scientific by 8.9%, now owning 39,503 shares valued at approximately $19.7 million.
• Insider trading reports revealed that executives sold a total of 29,666 shares worth around $14 million in the last three months, with a small percentage of stock (0.33%) owned by insiders.
• Thermo Fisher Scientific reported a 2.9% year-over-year revenue increase, with quarterly earnings exceeding expectations at $5.36 EPS on revenue of $10.86 billion.

Edmond DE Rothschild Holding S.A. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,503 shares of the medical research company's stock after buying an additional 3,236 shares during the period. Edmond DE Rothschild Holding S.A.'s holdings in Thermo Fisher Scientific were worth $19,657,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in TMO. Mondrian Investment Partners LTD grew its holdings in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after purchasing an additional 127,357 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares in the last quarter. Deutsche Bank AG increased its stake in Thermo Fisher Scientific by 9.5% in the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after acquiring an additional 114,277 shares during the period. Cetera Trust Company N.A increased its stake in Thermo Fisher Scientific by 3.3% in the first quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after acquiring an additional 150 shares during the period. Finally, Philip James Wealth Mangement LLC bought a new stake in Thermo Fisher Scientific in the first quarter valued at about $268,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $2.71 on Friday, reaching $492.20. The company's stock had a trading volume of 1,442,575 shares, compared to its average volume of 1,624,930. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The business's fifty day moving average price is $460.72 and its 200 day moving average price is $452.89. The company has a market cap of $185.86 billion, a price-to-earnings ratio of 28.47, a PEG ratio of 2.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday. Finally, Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $589.38.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,666 shares of company stock valued at $13,982,763 over the last 90 days. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.